조진균증 치료 시장 : 제품 유형별, 최종사용자별, 지역별 - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2030년)

Onychomycosis Treatment Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030

US $ 4,995 ￦ 7,411,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,823,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 12,604,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

세계 조진균증 치료 시장 규모는 2023년 510억 달러에 달하고, 연평균 7.6% 성장하여 2030년 말에는 851억 달러에 달할 것으로 전망됩니다.

주요 인사이트

조진균증 치료 시장 규모(2023E) : 510억 달러

예상 시장 규모(2030F) : 851억 달러

세계 시장 성장률(2023-2030년 CAGR) : 7.6%

과거 시장 성장률(CAGR 2018-2022년) : 4.9%

조진균증 치료 시장 - 연구 범위

조진균증 치료 시장 보고서는 시장 촉진요인, 억제요인, 기회 및 과제를 포함한 시장 역학에 대한 종합적인 분석을 제공합니다. 손발톱의 변색, 비후, 변형을 특징으로 하는 조진균증은 주로 피부사상균에 의해 발생하며, 의료 서비스 제공자에게 진단 및 치료 문제를 제시합니다. 이 보고서는 조진균증 치료의 뉘앙스를 탐구하고 시장 성장에 영향을 미치는 요인, 경쟁 환경, 항진균제 치료의 혁신을 촉진하는 새로운 동향을 조사합니다.

조진균증 치료 시장의 시장 촉진요인:

인구 고령화, 당뇨병, 면역 억제, 발 위생 불량 등의 요인으로 인한 조진균증의 유병률 증가는 조진균증 치료 시장의 주요 촉진요인입니다. 노인과 기저질환을 앓고 있는 환자는 면역기능 저하, 말초순환 저하, 손발톱의 구조적 변화로 인해 손발톱 진균 감염에 특히 취약하며, 적시에 진단과 치료 개입이 필요합니다.

또한 통증, 불편함, 부끄러움, 삶의 질 저하 등 조진균증의 임상적 및 심리사회적 영향에 대한 인식이 높아지면서 효과적인 치료 옵션에 대한 환자와 의사의 수요가 증가하고 있습니다. 조진균증 치료는 진균 병원균을 박멸하고, 손발톱의 건강을 회복하고, 질병의 재발을 방지하고, 환자에게 증상 완화와 미용적 개선을 제공하는 것을 목표로 합니다.

새로운 외용제, 내복약, 손발톱 박리 및 레이저 치료용 의료기기 개발 등 항진균 치료의 기술 발전은 치료 결과, 환자 순응도 및 치료 효과를 향상시키고 있습니다. 의료진과 환자의 변화하는 임상적 요구와 선호도에 대응하기 위해 각 제조업체들은 약물전달 시스템 혁신, 항진균력 강화, 치료 요법 최적화를 위한 연구개발에 투자하고 있습니다.

시장 억제요인

유망한 시장 전망에도 불구하고, 조진균증 치료 시장은 치료 내성, 안전성 문제, 규제 장벽 등의 도전에 직면해 있습니다. 손발톱 진균 감염은 손발톱의 느린 성장 속도, 손발톱 아래 잔여물의 존재, 항진균제 내성 등으로 인해 치료가 어려워 장기적이고 다각적인 치료 접근이 필요합니다.

또한, 경구용 아졸계 항진균제나 알릴아민계 항진균제와 같은 전신 항진균제는 부작용, 약물상호작용, 간독성을 동반할 수 있어 고령자나 간질환자 등 특정 환자군에서 유용성이 제한될 수 있습니다. 안전성 고려, 약물 내약성 및 치료 순응도는 손발톱 무좀 관리에서 치료법 선택과 환자 결과에 영향을 미치는 중요한 요소입니다.

시장 기회

조진균증 치료 시장에는 혁신, 협업, 시장 확대의 기회가 숨어 있습니다. 의료진균학, 피부약리학, 항진균제 개발의 진보를 활용하면 효능, 안전성, 환자 편의성을 개선한 차세대 치료제의 개발을 촉진할 수 있습니다.

또한, 제약사, 학계, 연구기관 간의 협력을 촉진하여 새로운 항진균제 및 치료제의 신약 개발 구상, 전임상 및 임상시험을 가속화할 수 있습니다. 유전체학, 프로테오믹스, 하이스루풋 스크리닝 기술을 활용하면 연구자들은 새로운 신약 타겟을 발굴하고, 기존 약물을 재사용하며, 손발톱 무좀 치료법을 최적화할 수 있습니다.

조진균증의 예방, 진단 및 치료에 대한 인식을 높이기 위한 교육적 이니셔티브는 의료진과 환자가 근거에 기반한 진료 방식을 채택하고 적시에 의료 개입을 요청할 수 있는 역량을 강화할 수 있습니다. 환자 교육 자료, 임상 진료 지침 및 지속적인 의학 교육 프로그램은 손발톱 무좀 관리에서 진단 정확도, 치료 순응도 및 장기적인 임상 결과를 개선하는 데 중요한 역할을 합니다.

보고서에서 답변한 주요 질문들

• 2030년 조진균증 치료 시장의 예상 CAGR은?
• 2023년 말 기준 조진균증 치료 세계 시장 규모는?
• 2023년 조진균증 치료 시장을 독점한 지역은 어디일까?
• 조진균증 치료 세계 시장에서 주요 플레이어는 누구인가?
• 시장 통합의 가장 큰 기회를 잡을 수 있는 조진균증 치료 부문은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
  • 주요 동향
• 치료 유형 수명주기 분석
• 조진균증 치료 시장 : 밸류체인
  • 원재료 공급업체 리스트
  • 제조업체 리스트
  • 판매대리점 리스트
  • 애플리케이션 리스트
  • 수익성 분석
• Porter’s Five Forces 분석
• 지정학적 긴장 : 시장에 대한 영향
• 거시경제적 요인
  • 세계의 부문별 전망
  • 세계의 GDP 성장률 전망
  • 세계의 상부 시장 개요
• 예측요인 - 관련성과 영향
• 규제와 테크놀러지 상황

제3장 세계의 조진균증 치료 시장 전망 : 과거(2018-2022년)와 예측(2023-2030년)

• 주요 하이라이트
  • 시장 수량(단위) 예측
  • 시장 규모와 전년비 성장률
  • 절대적 금액 기회
• 시장 규모(100만 달러) 분석과 예측
  • 과거 시장 규모 분석, 2013-2016년
  • 현재 시장 규모 예측, 2018-2026년
• 세계의 조진균증 치료 시장 전망 : 치료 유형
  • 소개/주요 조사 결과
  • 과거 시장 규모(100만 달러) 및 수량(단위) 분석 : 치료 유형별, 2018-2022년
  • 현재 시장 규모(100만 달러)와 수량(단위) 예측 : 치료 유형별, 2023-2030년
  • 시장 매력도 분석 : 치료 유형
• 세계의 조진균증 치료 시장 전망 : 적응 질환
  • 소개/주요 조사 결과
  • 과거 시장 규모(100만 달러) 및 수량(단위) 분석 : 적응 질환별, 2018-2022년
  • 현재 시장 규모(100만 달러)와 수량(단위) 예측 : 적응 질환별, 2023-2030년
  • 시장 매력도 분석 : 적응 질환
• 세계의 조진균증 치료 시장 전망 : 연령층
  • 소개/주요 조사 결과
  • 과거 시장 규모(100만 달러) 및 수량(단위) 분석 : 연령층별, 2018-2022년
  • 현재 시장 규모(100만 달러)와 수량(단위) 예측 : 연령층별, 2023-2030년
  • 시장 매력도 분석 : 연령층
• 세계의 조진균증 치료 시장 전망 : 유통 채널
  • 소개/주요 조사 결과
  • 과거 시장 규모(100만 달러) 및 수량(단위) 분석 : 유통 채널별, 2018-2022년
  • 현재 시장 규모(100만 달러)와 수량(단위) 예측 : 유통 채널별, 2023-2030년
  • 시장 매력도 분석 : 유통 채널

제4장 세계의 조진균증 치료 시장 전망 : 지역

• 주요 하이라이트
• 과거 시장 규모(100만 달러) 및 수량(단위) 분석 : 지역별, 2018-2022년
• 현재 시장 규모(100만 달러)와 수량(단위) 예측 : 지역별, 2023-2030년
  • 북미
  • 유럽
  • 동아시아
  • 남아시아와 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장 매력도 분석 : 지역

제5장 북미의 조진균증 치료 시장 전망 : 과거(2018-2022년)와 예측(2023-2030년)

제6장 유럽의 조진균증 치료 시장 전망 : 과거(2018-2022년)와 예측(2023-2030년)

제7장 동아시아의 조진균증 치료 시장 전망 : 과거(2018-2022년)와 예측(2023-2030년)

제8장 남아시아·오세아니아의 조진균증 치료 시장 전망 : 과거(2018-2022년)와 예측(2023-2030년)

제9장 라틴아메리카의 조진균증 치료 시장 전망 : 과거(2018-2022년)와 예측(2023-2030년)

제10장 중동 및 아프리카의 조진균증 치료 시장 전망 : 과거(2018-2022년)와 예측(2023-2030년)

제11장 경쟁 상황

• 시장 점유율 분석, 2022년
• 시장 구조
• 기업 개요
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Medimetriks Pharmaceuticals, Inc.
  • Galderma
  • Johnson & Johnson
  • Novartis AG
  • Moberg Pharma AB
  • Cardinal Health, Inc.
  • Pfizer Inc.
  • Almirall, SA
  • Bayer AG
  • Viatris Inc.
  • GlaxoSmithKline plc
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd

제12장 부록

ksm

영문 목차

영문목차

Persistence Market Research presents a comprehensive report on the global Onychomycosis Treatment Market, highlighting its substantial growth potential driven by the increasing prevalence of fungal nail infections and the rising demand for effective treatment options. Onychomycosis, a common fungal infection of the nails, poses significant clinical and aesthetic concerns, leading to a growing burden on healthcare systems and impacting patients' quality of life. The report emphasizes the critical need for innovative and efficacious treatments to address this prevalent dermatological condition effectively.

The global onychomycosis treatment market is forecast to expand at a CAGR of 7.6% and thereby increase from a value of US$51 Bn in 2023, to US$85.1 Bn by the end of 2030.

Key Insights

Onychomycosis Treatment Market Size (2023E): US$51 billion

Projected Market Value (2030F): US$85.1 billion

Global Market Growth Rate (CAGR 2023 to 2030): 7.6%

Historical Market Growth Rate (CAGR 2018 to 2022): 4.9%

Onychomycosis Treatment Market - Report Scope

The Onychomycosis Treatment Market report provides a comprehensive analysis of market dynamics, including drivers, restraints, opportunities, and challenges shaping the industry landscape. Onychomycosis, characterized by nail discoloration, thickening, and deformity, is predominantly caused by dermatophyte fungi, presenting diagnostic and therapeutic challenges for healthcare providers. The report delves into the nuances of onychomycosis treatment, examining factors influencing market growth, competitive landscape, and emerging trends driving innovation in antifungal therapies.

Market Growth Drivers for Onychomycosis Treatment Market:

The increasing prevalence of onychomycosis, attributed to factors such as aging demographics, diabetes mellitus, immunosuppression, and poor foot hygiene, is a primary driver for the onychomycosis treatment market. Elderly individuals and patients with underlying medical conditions are particularly susceptible to fungal nail infections due to compromised immune function, reduced peripheral circulation, and structural nail changes, necessitating timely diagnosis and treatment interventions.

Furthermore, the growing awareness about the clinical consequences and psychosocial impact of onychomycosis, including pain, discomfort, embarrassment, and impaired quality of life, is driving patient and physician demand for effective treatment options. Onychomycosis treatment aims to eradicate fungal pathogens, restore nail health, and prevent disease recurrence, offering symptomatic relief and cosmetic improvement for affected individuals.

Technological advancements in antifungal therapies, including the development of novel topical formulations, oral medications, and medical devices for nail debridement and laser therapy, are enhancing treatment outcomes, patient compliance, and therapeutic efficacy. Manufacturers are investing in research and development to innovate drug delivery systems, enhance antifungal potency, and optimize treatment regimens, aiming to address the evolving clinical needs and preferences of healthcare providers and patients.

Market Restraints

Despite the promising market outlook, the onychomycosis treatment market faces challenges related to treatment resistance, safety concerns, and regulatory barriers. Fungal nail infections can be challenging to treat due to the slow growth rate of nails, the presence of subungual debris, and the development of antifungal resistance, necessitating prolonged and multifaceted treatment approaches.

Moreover, systemic antifungal medications, such as oral azoles and allylamines, may be associated with adverse effects, drug interactions, and hepatotoxicity, limiting their utility in certain patient populations, including elderly individuals and those with liver impairment. Safety considerations, drug tolerability, and treatment adherence are crucial factors influencing treatment selection and patient outcomes in onychomycosis management.

Market Opportunities

Amidst the challenges lie opportunities for innovation, collaboration, and market expansion within the onychomycosis treatment market. Leveraging advancements in medical mycology, dermatopharmacology, and antifungal drug discovery can facilitate the development of next-generation therapies with improved efficacy, safety, and patient convenience.

Furthermore, fostering collaborations between pharmaceutical companies, academic institutions, and research organizations can accelerate drug development initiatives, preclinical studies, and clinical trials for novel antifungal agents and treatment modalities. By leveraging genomics, proteomics, and high-throughput screening technologies, researchers can identify new drug targets, repurpose existing medications, and optimize therapeutic regimens for onychomycosis.

Educational initiatives aimed at raising awareness about onychomycosis prevention, diagnosis, and treatment can empower healthcare providers and patients to adopt evidence-based practices and seek timely medical intervention. Patient education materials, clinical practice guidelines, and continuing medical education programs play a crucial role in improving diagnostic accuracy, treatment adherence, and long-term clinical outcomes in onychomycosis management.

Key Questions Answered in Report::

• What is the Forecast CAGR of the Onychomycosis Treatment Market in 2030?
• What is the Global Market Size of Onychomycosis Treatment as of the End of 2023?
• Which Region Dominated the Onychomycosis Treatment Market in 2023?
• Who are the Key Players in the Global Onychomycosis Treatment Market?
• Which Onychomycosis Treatment Segments Hold the Largest Opportunities for Market Integration?

Competitive Intelligence and Business Strategy

In navigating the competitive landscape, companies in the Onychomycosis Treatment Market must leverage competitive intelligence and strategic business initiatives to differentiate themselves and capitalize on emerging opportunities. Understanding market dynamics, customer preferences, and competitor strategies is essential for informed decision-making and market positioning.

Furthermore, investing in research and development, clinical trials, and regulatory compliance can help companies bring innovative therapies to market, gain regulatory approval, and expand market share. By focusing on patient-centric approaches, physician education, and market access strategies, companies can enhance product adoption, drive revenue growth, and improve patient outcomes in the dynamic Onychomycosis Treatment Market.

Key Companies Profiled

• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Medimetriks Pharmaceuticals, Inc.
• Galderma
• Johnson & Johnson
• Novartis AG
• Moberg Pharma AB
• Cardinal Health, Inc.
• Pfizer Inc.
• Almirall, S.A.
• Bayer AG
• Viatris Inc.
• GlaxoSmithKline plc
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd

Onychomycosis Treatment Market Research Segmentation

Market segmentation based on drug class, route of administration, distribution channel, and region provides valuable insights into key market segments and regional dynamics, enabling companies to tailor their offerings to specific customer needs and preferences. By understanding the unique requirements of different patient populations and geographic markets, companies can develop targeted strategies to address market demands effectively, thereby gaining a competitive edge and driving growth in the Onychomycosis Treatment Market.

Onychomycosis Treatment Market Research Segmentation

By Treatment Type:

• Drugs
• Oral
• Rx
• OTC
• Topical
• Rx
• OTC
• Lasers
• C02 Ablative Lasers
• Nd: YAG Lasers
• Dual-wavelength near-infrared Lasers
• Photodynamic Therapy

By Disease Indication:

• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candidal Onychomycosis
• Total Dystrophic Onychomycosis

By Age Group:

• 0 to 18 Years
• 18 to 39 Years
• 40 to 64 Years
• 65 Years & Above

By Distribution Channel:

• Institutional Sales
• Hospitals
• Dermatology Clinics
• Retail Sales
• Retail Pharmacies
• Drug Stores
• Mail Order Pharmacies & Online Sales

By Region:

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Onychomycosis Treatment Market Snapshot, 2023 and 2030
• 1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Treatment Type Lifecycle Analysis
• 2.4. Onychomycosis Treatment Market: Value Chain
  • 2.4.1. List of Raw Material Supplier
  • 2.4.2. List of Manufacturers
  • 2.4.3. List of Distributors
  • 2.4.4. List of Applications
  • 2.4.5. Profitability Analysis
• 2.5. Porter Five Force's Analysis
• 2.6. Geopolitical Tensions: Market Impact
• 2.7. Macro-Economic Factors
  • 2.7.1. Global Sectorial Outlook
  • 2.7.2. Global GDP Growth Outlook
  • 2.7.3. Global Parent Market Overview
• 2.8. Forecast Factors - Relevance and Impact
• 2.9. Regulatory and Technology Landscape

3. Global Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 3.1. Key Highlights
  • 3.1.1. Market Volume (Units) Projections
  • 3.1.2. Market Size and Y-o-Y Growth
  • 3.1.3. Absolute $ Opportunity
• 3.2. Market Size (US$ Mn) Analysis and Forecast
  • 3.2.1. Historical Market Size Analysis, 2013-2016
  • 3.2.2. Current Market Size Forecast, 2018-2026
• 3.3. Global Onychomycosis Treatment Market Outlook: Treatment Type
  • 3.3.1. Introduction / Key Findings
  • 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Treatment Type, 2018 - 2022
  • 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
    • 3.3.3.1. Drugs
      • 3.3.3.1.1. Oral
      • 3.3.3.1.2. Rx
      • 3.3.3.1.3. OTC
      • 3.3.3.1.4. Topical
      • 3.3.3.1.5. Rx
      • 3.3.3.1.6. OTC
    • 3.3.3.2. Lasers
      • 3.3.3.2.1. C02 Ablative Lasers
      • 3.3.3.2.2. Nd: YAG Lasers
      • 3.3.3.2.3. Dual-wavelength near-infrared Lasers
    • 3.3.3.3. Photodynamic Therapy
• 3.4. Market Attractiveness Analysis: Treatment Type
• 3.5. Global Onychomycosis Treatment Market Outlook: Disease Indication
  • 3.5.1. Introduction / Key Findings
  • 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Disease Indication, 2018 - 2022
  • 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
    • 3.5.3.1. Distal Subungual Onychomycosis
    • 3.5.3.2. White Superficial Onychomycosis
    • 3.5.3.3. Proximal Subungual Onychomycosis
    • 3.5.3.4. Candidal Onychomycosis
    • 3.5.3.5. Total Dystrophic Onychomycosis
• 3.6. Market Attractiveness Analysis: Disease Indication
• 3.7. Global Onychomycosis Treatment Market Outlook: Age Group
  • 3.7.1. Introduction / Key Findings
  • 3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Age Group, 2018 - 2022
  • 3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
    • 3.7.3.1. 0 to 18 Years
    • 3.7.3.2. 18 to 39 Years
    • 3.7.3.3. 40 to 64 Years
    • 3.7.3.4. 65 Years & Above
• 3.8. Market Attractiveness Analysis: Age Group
• 3.9. Global Onychomycosis Treatment Market Outlook: Distribution Channel
  • 3.9.1. Introduction / Key Findings
  • 3.9.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Distribution Channel, 2018 - 2022
  • 3.9.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
    • 3.9.3.1. Institutional Sales
    • 3.9.3.2. Hospitals
    • 3.9.3.3. Dermatology Clinics
    • 3.9.3.4. Retail Sales
    • 3.9.3.5. Retail Pharmacies
    • 3.9.3.6. Drug Stores
    • 3.9.3.7. Mail Order Pharmacies & Online Sales
• 3.10. Market Attractiveness Analysis: Distribution Channel

4. Global Onychomycosis Treatment Market Outlook: Region

• 4.1. Key Highlights
• 4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
• 4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
  • 4.3.1. North America
  • 4.3.2. Europe
  • 4.3.3. East Asia
  • 4.3.4. South Asia and Oceania
  • 4.3.5. Latin America
  • 4.3.6. Middle East & Africa (MEA)
• 4.4. Market Attractiveness Analysis: Region

5. North America Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 5.1. Key Highlights
• 5.2. Pricing Analysis
• 5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 5.3.1. By Country
  • 5.3.2. By Treatment Type
  • 5.3.3. By Disease Indication
  • 5.3.4. By Age Group
  • 5.3.5. By Distribution Channel
• 5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 5.4.1. U.S.
  • 5.4.2. Canada
• 5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
  • 5.5.1. Drugs
    • 5.5.1.1. Oral
    • 5.5.1.2. Rx
    • 5.5.1.3. OTC
    • 5.5.1.4. Topical
    • 5.5.1.5. Rx
    • 5.5.1.6. OTC
  • 5.5.2. Lasers
    • 5.5.2.1. C02 Ablative Lasers
    • 5.5.2.2. Nd: YAG Lasers
    • 5.5.2.3. Dual-wavelength near-infrared Lasers
  • 5.5.3. Photodynamic Therapy
• 5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
  • 5.6.1. Distal Subungual Onychomycosis
  • 5.6.2. White Superficial Onychomycosis
  • 5.6.3. Proximal Subungual Onychomycosis
  • 5.6.4. Candidal Onychomycosis
  • 5.6.5. Total Dystrophic Onychomycosis
• 5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
  • 5.7.1. 0 to 18 Years
  • 5.7.2. 18 to 39 Years
  • 5.7.3. 40 to 64 Years
  • 5.7.4. 65 Years & Above
• 5.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
  • 5.8.1. Institutional Sales
  • 5.8.2. Hospitals
  • 5.8.3. Dermatology Clinics
  • 5.8.4. Retail Sales
  • 5.8.5. Retail Pharmacies
  • 5.8.6. Drug Stores
  • 5.8.7. Mail Order Pharmacies & Online Sales
• 5.9. Market Attractiveness Analysis

6. Europe Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 6.1. Key Highlights
• 6.2. Pricing Analysis
• 6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 6.3.1. By Country
  • 6.3.2. By Treatment Type
  • 6.3.3. By Disease Indication
  • 6.3.4. By Age Group
  • 6.3.5. By Distribution Channel
• 6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 6.4.1. Germany
  • 6.4.2. France
  • 6.4.3. U.K.
  • 6.4.4. Italy
  • 6.4.5. Spain
  • 6.4.6. Russia
  • 6.4.7. Turkiye
  • 6.4.8. Rest of Europe
• 6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
  • 6.5.1. Drugs
    • 6.5.1.1. Oral
    • 6.5.1.2. Rx
    • 6.5.1.3. OTC
    • 6.5.1.4. Topical
    • 6.5.1.5. Rx
    • 6.5.1.6. OTC
  • 6.5.2. Lasers
    • 6.5.2.1. C02 Ablative Lasers
    • 6.5.2.2. Nd: YAG Lasers
    • 6.5.2.3. Dual-wavelength near-infrared Lasers
  • 6.5.3. Photodynamic Therapy
• 6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
  • 6.6.1. Distal Subungual Onychomycosis
  • 6.6.2. White Superficial Onychomycosis
  • 6.6.3. Proximal Subungual Onychomycosis
  • 6.6.4. Candidal Onychomycosis
  • 6.6.5. Total Dystrophic Onychomycosis
• 6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
  • 6.7.1. 0 to 18 Years
  • 6.7.2. 18 to 39 Years
  • 6.7.3. 40 to 64 Years
  • 6.7.4. 65 Years & Above
• 6.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
  • 6.8.1. Institutional Sales
  • 6.8.2. Hospitals
  • 6.8.3. Dermatology Clinics
  • 6.8.4. Retail Sales
  • 6.8.5. Retail Pharmacies
  • 6.8.6. Drug Stores
  • 6.8.7. Mail Order Pharmacies & Online Sales
• 6.9. Market Attractiveness Analysis

7. East Asia Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 7.3.1. By Country
  • 7.3.2. By Treatment Type
  • 7.3.3. By Disease Indication
  • 7.3.4. By Age Group
  • 7.3.5. By Distribution Channel
• 7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 7.4.1. China
  • 7.4.2. Japan
  • 7.4.3. South Korea
• 7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
  • 7.5.1. Drugs
    • 7.5.1.1. Oral
    • 7.5.1.2. Rx
    • 7.5.1.3. OTC
    • 7.5.1.4. Topical
    • 7.5.1.5. Rx
    • 7.5.1.6. OTC
  • 7.5.2. Lasers
    • 7.5.2.1. C02 Ablative Lasers
    • 7.5.2.2. Nd: YAG Lasers
    • 7.5.2.3. Dual-wavelength near-infrared Lasers
  • 7.5.3. Photodynamic Therapy
• 7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
  • 7.6.1. Distal Subungual Onychomycosis
  • 7.6.2. White Superficial Onychomycosis
  • 7.6.3. Proximal Subungual Onychomycosis
  • 7.6.4. Candidal Onychomycosis
  • 7.6.5. Total Dystrophic Onychomycosis
• 7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
  • 7.7.1. 0 to 18 Years
  • 7.7.2. 18 to 39 Years
  • 7.7.3. 40 to 64 Years
  • 7.7.4. 65 Years & Above
• 7.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
  • 7.8.1. Institutional Sales
  • 7.8.2. Hospitals
  • 7.8.3. Dermatology Clinics
  • 7.8.4. Retail Sales
  • 7.8.5. Retail Pharmacies
  • 7.8.6. Drug Stores
  • 7.8.7. Mail Order Pharmacies & Online Sales
• 7.9. Market Attractiveness Analysis

8. South Asia & Oceania Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 8.3.1. By Country
  • 8.3.2. By Treatment Type
  • 8.3.3. By Disease Indication
  • 8.3.4. By Age Group
  • 8.3.5. By Distribution Channel
• 8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 8.4.1. India
  • 8.4.2. Southeast Asia
  • 8.4.3. ANZ
  • 8.4.4. Rest of South Asia & Oceania
• 8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
  • 8.5.1. Drugs
    • 8.5.1.1. Oral
    • 8.5.1.2. Rx
    • 8.5.1.3. OTC
    • 8.5.1.4. Topical
    • 8.5.1.5. Rx
    • 8.5.1.6. OTC
  • 8.5.2. Lasers
    • 8.5.2.1. C02 Ablative Lasers
    • 8.5.2.2. Nd: YAG Lasers
    • 8.5.2.3. Dual-wavelength near-infrared Lasers
  • 8.5.3. Photodynamic Therapy
• 8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
  • 8.6.1. Distal Subungual Onychomycosis
  • 8.6.2. White Superficial Onychomycosis
  • 8.6.3. Proximal Subungual Onychomycosis
  • 8.6.4. Candidal Onychomycosis
  • 8.6.5. Total Dystrophic Onychomycosis
• 8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
  • 8.7.1. 0 to 18 Years
  • 8.7.2. 18 to 39 Years
  • 8.7.3. 40 to 64 Years
  • 8.7.4. 65 Years & Above
• 8.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
  • 8.8.1. Institutional Sales
  • 8.8.2. Hospitals
  • 8.8.3. Dermatology Clinics
  • 8.8.4. Retail Sales
  • 8.8.5. Retail Pharmacies
  • 8.8.6. Drug Stores
  • 8.8.7. Mail Order Pharmacies & Online Sales
• 8.9. Market Attractiveness Analysis

9. Latin America Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 9.3.1. By Country
  • 9.3.2. By Treatment Type
  • 9.3.3. By Disease Indication
  • 9.3.4. By Age Group
  • 9.3.5. By Distribution Channel
• 9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America
• 9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
  • 9.5.1. Drugs
    • 9.5.1.1. Oral
    • 9.5.1.2. Rx
    • 9.5.1.3. OTC
    • 9.5.1.4. Topical
    • 9.5.1.5. Rx
    • 9.5.1.6. OTC
  • 9.5.2. Lasers
    • 9.5.2.1. C02 Ablative Lasers
    • 9.5.2.2. Nd: YAG Lasers
    • 9.5.2.3. Dual-wavelength near-infrared Lasers
  • 9.5.3. Photodynamic Therapy
• 9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
  • 9.6.1. Distal Subungual Onychomycosis
  • 9.6.2. White Superficial Onychomycosis
  • 9.6.3. Proximal Subungual Onychomycosis
  • 9.6.4. Candidal Onychomycosis
  • 9.6.5. Total Dystrophic Onychomycosis
• 9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
  • 9.7.1. 0 to 18 Years
  • 9.7.2. 18 to 39 Years
  • 9.7.3. 40 to 64 Years
  • 9.7.4. 65 Years & Above
• 9.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
  • 9.8.1. Institutional Sales
  • 9.8.2. Hospitals
  • 9.8.3. Dermatology Clinics
  • 9.8.4. Retail Sales
  • 9.8.5. Retail Pharmacies
  • 9.8.6. Drug Stores
  • 9.8.7. Mail Order Pharmacies & Online Sales
• 9.9. Market Attractiveness Analysis

10. Middle East & Africa Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 10.3.1. By Country
  • 10.3.2. By Treatment Type
  • 10.3.3. By Disease Indication
  • 10.3.4. By Age Group
  • 10.3.5. By Distribution Channel
• 10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 10.4.1. GCC
  • 10.4.2. Egypt
  • 10.4.3. South Africa
  • 10.4.4. Northern Africa
  • 10.4.5. Rest of Middle East & Africa
• 10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
  • 10.5.1. Drugs
    • 10.5.1.1. Oral
    • 10.5.1.2. Rx
    • 10.5.1.3. OTC
    • 10.5.1.4. Topical
    • 10.5.1.5. Rx
    • 10.5.1.6. OTC
  • 10.5.2. Lasers
    • 10.5.2.1. C02 Ablative Lasers
    • 10.5.2.2. Nd: YAG Lasers
    • 10.5.2.3. Dual-wavelength near-infrared Lasers
  • 10.5.3. Photodynamic Therapy
• 10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
  • 10.6.1. Distal Subungual Onychomycosis
  • 10.6.2. White Superficial Onychomycosis
  • 10.6.3. Proximal Subungual Onychomycosis
  • 10.6.4. Candidal Onychomycosis
  • 10.6.5. Total Dystrophic Onychomycosis
• 10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
  • 10.7.1. 0 to 18 Years
  • 10.7.2. 18 to 39 Years
  • 10.7.3. 40 to 64 Years
  • 10.7.4. 65 Years & Above
• 10.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
  • 10.8.1. Institutional Sales
  • 10.8.2. Hospitals
  • 10.8.3. Dermatology Clinics
  • 10.8.4. Retail Sales
  • 10.8.5. Retail Pharmacies
  • 10.8.6. Drug Stores
  • 10.8.7. Mail Order Pharmacies & Online Sales
• 10.9. Market Attractiveness Analysis

11. Competition Landscape

• 11.1. Market Share Analysis, 2022
• 11.2. Market Structure
  • 11.2.1. Competition Intensity Mapping By Market
  • 11.2.2. Competition C02 Ablative Lasers
  • 11.2.3. Apparent Product Capacity
• 11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 11.3.1. Teva Pharmaceutical Industries Ltd.
    • 11.3.1.1. Overview
    • 11.3.1.2. Segments and Product
    • 11.3.1.3. Key Financials
    • 11.3.1.4. Market Developments
    • 11.3.1.5. Market Strategy
  • 11.3.2. Sanofi S.A.
    • 11.3.2.1. Overview
    • 11.3.2.2. Segments and Product
    • 11.3.2.3. Key Financials
    • 11.3.2.4. Market Developments
    • 11.3.2.5. Market Strategy
  • 11.3.3. Medimetriks Pharmaceuticals, Inc.
    • 11.3.3.1. Overview
    • 11.3.3.2. Segments and Product
    • 11.3.3.3. Key Financials
    • 11.3.3.4. Market Developments
    • 11.3.3.5. Market Strategy
  • 11.3.4. Galderma
    • 11.3.4.1. Overview
    • 11.3.4.2. Segments and Product
    • 11.3.4.3. Key Financials
    • 11.3.4.4. Market Developments
    • 11.3.4.5. Market Strategy
  • 11.3.5. Johnson & Johnson
    • 11.3.5.1. Overview
    • 11.3.5.2. Segments and Product
    • 11.3.5.3. Key Financials
    • 11.3.5.4. Market Developments
    • 11.3.5.5. Market Strategy
  • 11.3.6. Novartis AG
    • 11.3.6.1. Overview
    • 11.3.6.2. Segments and Product
    • 11.3.6.3. Key Financials
    • 11.3.6.4. Market Developments
    • 11.3.6.5. Market Strategy
  • 11.3.7. Moberg Pharma AB
    • 11.3.7.1. Overview
    • 11.3.7.2. Segments and Product
    • 11.3.7.3. Key Financials
    • 11.3.7.4. Market Developments
    • 11.3.7.5. Market Strategy
  • 11.3.8. Cardinal Health, Inc.
    • 11.3.8.1. Overview
    • 11.3.8.2. Segments and Product
    • 11.3.8.3. Key Financials
    • 11.3.8.4. Market Developments
    • 11.3.8.5. Market Strategy
  • 11.3.9. Pfizer Inc.
    • 11.3.9.1. Overview
    • 11.3.9.2. Segments and Product
    • 11.3.9.3. Key Financials
    • 11.3.9.4. Market Developments
    • 11.3.9.5. Market Strategy
  • 11.3.10. Almirall, S.A.
    • 11.3.10.1. Overview
    • 11.3.10.2. Segments and Product
    • 11.3.10.3. Key Financials
    • 11.3.10.4. Market Developments
    • 11.3.10.5. Market Strategy
  • 11.3.11. Bayer AG
    • 11.3.11.1. Overview
    • 11.3.11.2. Segments and Product
    • 11.3.11.3. Key Financials
    • 11.3.11.4. Market Developments
    • 11.3.11.5. Market Strategy
  • 11.3.12. Viatris Inc.
    • 11.3.12.1. Overview
    • 11.3.12.2. Segments and Product
    • 11.3.12.3. Key Financials
    • 11.3.12.4. Market Developments
    • 11.3.12.5. Market Strategy
  • 11.3.13. GlaxoSmithKline plc
    • 11.3.13.1. Overview
    • 11.3.13.2. Segments and Product
    • 11.3.13.3. Key Financials
    • 11.3.13.4. Market Developments
    • 11.3.13.5. Market Strategy
  • 11.3.14. Cipla Ltd.
    • 11.3.14.1. Overview
    • 11.3.14.2. Segments and Product
    • 11.3.14.3. Key Financials
    • 11.3.14.4. Market Developments
    • 11.3.14.5. Market Strategy
  • 11.3.15. Dr. Reddy's Laboratories Ltd
    • 11.3.15.1. Overview
    • 11.3.15.2. Segments and Product
    • 11.3.15.3. Key Financials
    • 11.3.15.4. Market Developments
    • 11.3.15.5. Market Strategy

12. Appendix

• 12.1. Research Methodology
• 12.2. Research Assumptions
• 12.3. Acronyms and Abbreviations

관련자료